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INTRODUCTION 
In recent years, considerable attention has been focused 
on the development of novel drug delivery systems 
(NDDS). The reason for this significant shift is relatively 
low development cost and time required for introducing 
NDDS ($ 20-50 million and 3-4 years respectively) as 
compared to new molecule. (approximately $500 million 
to $ 1 billion and 10-12 years, respectively). In the form 
of NDDS, an existing drug molecule can get a “new 
life”, thereby increasing its market value, 
competitiveness, and patent life1. Approximately 40% of 
new drug candidates have poor water solubility and the 
oral delivery of such drugs is frequently associated with 
low bioavailability, high intra-subject and inter subject 
variability, and a lack of dose proportionality. If a drug 
candidate has reasonable membrane permeability, then 
often the rate limiting process of absorption is the 
dissolution of dug in gastrointestinal lumen. This is a 
characteristics of compounds classified as 
Biopharmaceutical Classification system (BCS) Class II 
drugs2. The issue arose in particular when drug discovery 
moved from wet chemistry to combinatorial chemistry 
and high throughput screening in mid 1990’s. The 
properties of new chemical entities shifted towards 
higher molecular weight and increasing lipophilicity, 
resulting in decreased aqueous solubility.. 
Several strategies to improve the solubility and 
dissolution of poorly water soluble drugs have been 
developed and described in literature, which were at start 
primarily based on modifying the drug’s 
physicochemical properties. Particle size reduction and 
salt formation became frequently taken paths in a quest 
for dissolution improvement, but both methods revealed 
limitations 3, 4. As a result, altering drug solubility or 
dissolution through formulation approaches has become 
more and more popular. Formulation plays a major role 
in determining the rate and extent of absorption of such a 
drugs from the gastrointestinal tract.  
Lipid-based formulations for lymphatic delivery 
The lymphatic system is an extensive drainage network 
spread throughout all areas of the body. It shadows the 
blood circulation system and functions mainly to return 
ﬂuid, which has leaked into the interstitial space, back to 
ABSTRACT 
Objective: The objective of the study was to design and develop self-microemulsifying osmotic pump tablet Isradipine, a BCS 
Class IV antihypertensive agent for improved solubility and obtain controlled release characteristics. 
Material & Methods: Methodology for undertaken project involved pre-formulation studies, comprising of analytical method 
adoption and drug: excipient compatibility studies. Further steps involve formulation and characterization of liquid SMEDDS 
of Isradipine. Developed SMEDDS was incorporated into selected adsorbent and compressed with osmotic agents, a binder 
and lubricant into tablet. Tablets were film coated with semi-permeable membrane and drilled with orifice. Final formulation 
was optimized for various formulation components and evaluated on various dimensions, among dissolution profiling and 
stability studies. 
Results and Discussion: Solubility studies in oils, surfactants and co-surfactants were carried out and SMEDDS formulation 
was finalized as Isradipine (11.63%), Gelucire 50/13 (34.88%), Lutrol F127 (30.23%) and Transcutol P (23.26%). Neusilin US 
2 was selected as adsorbent in 1:1 ratio based on excellent adsorption and huge surface area. Final optimized formulation of 
tablet comprises of core tablet and functional coatings of cellulose acetate (60%) and PEG 400 (40%) with 5% film coating 
build up. Developed formulation was optimized for various formulation components and evaluated for release kinetics and 
accelerated stability study. 
Conclusion: The developed novel SME-OPT of Isradipine will be a promising template for formulating controlled release 
dosage form of BCS Class II and IV bioactive agents. The technology used for the preparation of SME-OPT is relatively 
simple manufacturing technology which can be easily adopted in industrial units on a commercial scale. 
Keywords: Self-microemulsifying osmotic pump, Isradipine, Improved solubility 
Yeramwar et al              JDDT; Special Issue1: "Drug Delivery using Nanomedicine & Nanotechnology"          29 
© 2011-14, JDDT. All Rights Reserved                                                ISSN: 2250-1177                                                CODEN (USA): JDDTAO 
the blood. Advantages of drug delivery to the intestinal 
lymphatic system include; avoidance of hepatic ﬁrst pass 
metabolism and the potential to target speciﬁc disease 
states known to spread via the lymphatic’s for example - 
certain lymphomas and HIV 5. 
Self Micro-emulsifying Drug Delivery Systems 
(SMEDDS) 
Self micro-emulsifying drug delivery systems 
(SMEDDS) are defined as isotropic mixtures of natural 
or synthetic oils, solids or liquid surfactants or 
alternatively, one or more hydrophilic solvents, and co-
solvents or co-surfactants [5]. SMEDDS are able to self 
micro-emulsify rapidly into fine O/W microemulsion in 
the gastrointestinal fluids, under gentle agitation 
provided by the gastrointestinal tract. This fine O/W 
emulsion results in small droplets of oil dispersed in the  
gastrointestinal fluids that provide a large interfacial area 
enhancing the activity and minimizing the irritation due 
to contact of drug in the gut wall. Self microemulsifying 
System (SMES) can be formulated with little energy 
input and the shelf life is longer than conventional 
emulsions
1, 06-10
. Self emulsifying drug delivery systems 
(SEDDS) typically produce emulsion with a droplet size 
between 100 to 300 nm, while self micro-emulsifying 
drug delivery system (SMEDDS) form transparent 
micro-emulsions with a droplet size of less than 100 nm. 
The excipients used in SEDDS or SMEDDS are oils, 
surfactants, co-solvents, co- surfactants 9,10. 
Solid Self Micro-emulsifying Drug Delivery System 
(S-SMEDDS)  
SMEDDS are normally prepared as liquid dosage forms 
that can be administrated in soft gelatine capsules, which 
have some disadvantages especially in the manufacturing 
process 11. Given the advantages of solid dosage forms, 
S- SMEDDS have been extensively exploited in recent 
years, as they frequently represent more effective 
alternatives to conventional liquid SMEDDS. From the 
perspective of dosage forms, S-SMEDDS means solid 
dosage forms with self micro-emulsification properties. 
S-SMEDDS focus on the incorporation of liquid/ 
semisolid self microemulsifying ingredients into 
powders/ nanoarticles by different solidification 
techniques (e.g. adsorptions to solid carriers, spray 
drying, melt extrusion, nanoparticle technology, and so 
on). To some extent, S-SMEDDS are combinations of 
SMEDDS and solid dosage forms, so many properties of 
S-SMEDDS (e.g. excipients selection, specificity, and 
characterization) are the sum of the corresponding 
properties of both SMEDDS and solid dosage forms 12.  
Oral controlled release system and Osmotic Drug 
Delivery System (ODDS) 
Controlled release delivery systems provide desired 
concentration of drug at the absorption site allowing 
maintenance of plasma concentrations within the 
therapeutic range and reducing the dosing frequency. 
These products typically provide significant benefits 
over immediate-release formulations, including greater 
effectiveness in the treatment of chronic conditions, 
reduced side effects, and greater patient convenience due 
to a simplified dosing schedule 13.  Using osmotic 
pressure as the energy source, the semipermeable 
membrane controls water inflow, generating 
hydrodynamic pressure inside the device and, thereby 
controlling drug delivery.  
Rationale for design of self emulsifying osmotic 
delivery system 
Ideal oral drug controlled delivery systems are those that 
steadily meter out a measurable, reproducible amount of 
the drug over a prolonged period. In recent years much 
attention has been focused on lipid-microemulsion 
formulations with particular emphasis on self-
microemulsifying or self emulsifying drug delivery 
systems to improve oral bioavailability of poorly water-
soluble drugs and lipophilic drugs. A new formulation 
can be developed which combines the advantage of 
SMEDDS and controlled drug delivery system and 
exhibit synergistic desired release profile 14-18. 
Drug profile- Isradipine 
Isradipine is a calcium channel antagonist. It is available 
for once-daily oral administration as a controlled-release 
5-mg and 10-mg tablet. Isradipine is mainly used for the 
treatment of hypertension, angina pectoris. Successful 
treatment can be achieved by maintaining constant & 
uniform therapeutic plasma drug concentration. 
Isradipine has plasma half life 1.5 to 2 hr; therefore it 
needs to be taken two/three times a day (depending upon 
disease condition). Drug has poor bioavailability (15-
24%) which is mainly due to extensive pre-systemic & 
gastrointestinal metabolism and poor solubility 19-22. A 
formulation of Isradipine which could increase 
bioavailability through improvement of solubility, first 
pass avoidance and at the same time also release 
Isradipine for an extended period of time, thereby 
improving patient compliance will be highly appreciated 
22. In present work we intended to develop a system 
wherein, solid self microemulsifying system will 
solubilize drug and also avoid first pass effect by 
lymphatic absorption, moreover combination of this 
system with osmotic system will provide controlled 
release of drug. 
MATERIALS & METHODS 
MATERIALS  
Isradipine was obtained as a gift sample from Glaxo 
Smith Kline Pharmaceuticals Ltd., Nashik, India; 
Gelucire 44/14, Gelucire 50/13 and Transcutol P was 
obtained from Gattefosse india Private Limited, Mumbai, 
India. Samples of Lutrol F127 were obtained from 
BASF, India. Grades of Zeopharm (5170 and 177) and 
Neusilin US 2 was obtained from J.M. Huber 
Corporation, India. Different grades of Aerosil and 
Aeroperl obtained from Degussa, India. PEG400, 
cellulose acetate, Methocel E3LV was generous gift 
from Signet Chemical Corporation, Mumbai. Distilled 
water was freshly prepared and used for the study. All 
the chemicals and reagents were of analytical reagent 
(AR) grade and used without further purifications. 
METHODS 
Analytical method for estimation of Isradipine 
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UV spectrophotometric method for estimation of 
Isradipine was adopted from USP. The calibration curve 
was plotted to determine unknown concentration of the 
drug. The mean absorbance (at 328 nm) and versus the 
concentration of respective standard was plotted to 
obtain the curve. The drug solution in 5:95 ratio mixture 
of methanol and 0.1% aqueous solution of lauryl 
dimethyl amine oxide having concentration of 5, 10, 15, 
20, 25 µg/ml were analyzed at λmax 328 nm
23. 
Drug-Excipients Compatibility Study 
To select suitable excipients for the formulation of 
Isradipine Self microemulsifying osmotic pump tablet 
(SME-OPT), the mixture of Isradipine drug substance 
with various excipients were prepared in different ratio 
and exposed at 40ºC ± 2ºC / 75% ± 5% RH in glass vials 
for 4 weeks. The samples were evaluated for any change 
in the physical characteristics and description and also 
analyzed for the drug content at initial and after 4 weeks 
exposure. 
Formulation of liquid self microemulsifying system of 
Isradipine 
Solubility Studies in oils, surfactants and co-
surfactants: The solubility of Isradipine was determined 
in various solvents, surfactants, co-surfactants and oils. 
An excess amount of Isradipine was added to 1.5 ml 
snap-cap Eppendorf tube containing various additives. 
The resulting mixture was sufficiently mixed and then 
placed in a constant temperature water bath at 37°C for 3 
days. Aliquots were centrifuged at 10,000 rpm for 10 
min. The supernatant layer was carefully collected and 
then adjusted with a proper dilution. The concentration 
of Isradipine was analyzed by spectrophotometric 
method at 328 nm after dilution with methanol. 
Solubility Studies of isradipine in various ratio of 
surfactant ratio: Solubility of isradipine in various 
ratios of surfactants, and co-surfactants was carried out 
by adding excess amount of isradipine into the 1.5 ml 
snap-cap Eppendorf tube. The resulting mixture was 
sufficiently mixed and then placed in a constant 
temperature water bath at 37°C for 3 days. Aliquots were 
centrifuged at 10,000 rpm for 10 min. The supernatant 
layer was carefully collected and then adjusted with a 
proper dilution. The concentration of Isradipine was 
analyzed by spectrophotometric method at 328 nm after 
dilution with methanol. 
Preparation of liquid SMEDDS formulations: 
Isradipine, surfactant and fatty acid were homogenously 
mixed together based on the formulation compositions. 
The resulting mixtures were slightly heated at various 
temperatures and sufficiently stirred. The mixture was 
kept heating at 60°C until all the materials were melted. 
The obtained mixture was mixed by vortex until a clear 
solution formed. The mixture was self-microemulsifying 
non aqueous base. 
Characterization of liquid SMEDDS 
Particle size measurement: Self microemulsifying 
system was diluted by 100 times with distilled water, and 
then droplet size of the resultant emulsion was 
determined by Zeta sizer nano ZS90. The mean droplet 
size and polydispersity index of the liquid SMEDDS was 
recorded. 
Percent transmittance: The percent transmittance of 
diluted SMEDDS (1 ml to 100 ml) in distilled water was 
measured at 650 nm using UV visible double beam 
spectrophotometer. 
Dilution Potential: The prepared formulation was 
diluted 100 times with continuous media (distilled 
water), and appearance recorded. 
Zeta Potential: Measurement of zeta potential has 
become inextricably connected with the study and 
characterization of colloidal dispersions, as this 
parameter is highly useful for the assessment of the 
physical stability of colloidal dispersions. In the present 
work, for the zeta potential measurements Zetasizer 
Nano ZS90 (Malvern Instruments Inc., U.K.) had been 
employed. Clear disposable zeta cell made up of 
polystyrene was used for measurement. The instrument 
settings used were;  temperature 25° C, viscosity 0.8872 
centipoise, dispersant refractive index 1.33, material 
refractive index 1.58 and run time 10 sec for each run. 
Formulation of Solid SMEDDS 
Preparation of solid self emulsifying adsorbate: The 
melted SMEDDS solution was added to various 
adsorbents. After mixing it for 15 minutes in blender, the 
mixtures were cooled at 2-8°C for 2 hours. The solidified 
mass was pulverized thoroughly by a pestle and mortar 
and finally, passed through a 40 mesh sieve to obtain free 
flowing solid SMEDDS powder. 
Reconstitution properties of S-SMEDDS: Solid self-
micro-emulsifying drug delivery systems (S-SMEDDS) 
were dispersed in water under stirring for 30 min at 25 ± 
0.5°C. Dispersion was filtered through 0.45 um filter to 
separate insoluble adsorbent component. The average 
droplet size and polydispersity index of microemulsion 
obtained from re-dispersed solid SMEDDS were 
determined by Zeta Sizer Nano ZS90 
Formulation of self microemulsifying osmotic pump 
tablet (SME-OPT) 
Preparation of core tablets: Solid self 
microemulsifying adsorbate, lactose or fructose or 
selected osmotic agent, citric acid and sodium 
bicarbonate were blended for 15 minutes in blender. 
After pre-lubrication, the mixture was screened through 
40 mesh sieve. This  was followed by lubrication 
blending for 5 minutes after addition of 1% (w/w) 
magnesium stearate and finally compression using tablet 
compression machine with an 11 mm standard concave 
punch to obtain a 600 mg (or as per trial) tablet with 
hardness of 6.0 –8.0 kp determined using tablet hardness 
tester. 
Table 1 provides list of ingredients used in various trials 
with their functional category. 
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Table 1: List of ingredients used in various trials and their functional category 
S. No. Ingredient Grade Function of ingredient 
Core tablet componants 
1 
Isradipine Solid SMEDDS 
Adsorbate 
-- Drug- Adsorbent 
2 Lactose Pharmatose 
Osmotic agent 3 Mannitol Perlitol 
4 Fructose -- 
5 
Hydroxypropyl methyl 
cellulose 3 cps 
Methocel E3 LV Binder 
6 Citric acid -- 
Carbonated system 
7 Sodium bicarbonate -- 
8 Magnesium stearate Vegetable Grade Lubricant 
Coating componants 
9 Cellulose acetate -- Coating polymer 
10 PEG 400 -- Plasticizer 
11 Acetone -- Solvent 
12 Methanol -- Solvent 
 
Coating of core tablets with Cellulose Acetate: 
Cellulose Acetate was dissolved in acetone: methanol 
(70:30), and PEG 400 was used as plasticizer. Initially 
cellulose acetate and PEG 400 were dispersed with the 
help of methanol; complete solubilzation of cellulose 
acetate was achieved by use of acetone. Core tablets 
were coated with above solution to obtain coated tablets 
with predetermined weight gains (examples are 5, 7 and 
9%) using R & D coater. Coating composition & Coating 
processing parameters are listed in table 1 & 2 
respectively.
 
Table 2: Tablet Coating Parameters 
 
 
Orifice Drilling: An appropriate size (0.8 mm or as per 
trial) was created on one face of the tablet through the 
coating membranes using mechanical drill. Tablets of 
each batch were cured at 40 ºC for 12 hour before 
evaluation. 
Evaluation of core tablet 
Compressed core teblets were evaluated for general 
appearance, weight variation, tablet thickness, hardness, 
friability and drug content by compendia methods. 
EVALUATION of SME-OPT 
Physical Characterization of Isradipine in SME-OPT 
When self-microemulsifying drug delivery system was 
prepared into solid dosage form, it might be important to 
identify the physical characterization of the drug in the 
dosage form. For the physical characterization, sample of 
Isradipine, placebo mixture, physical mixture and solid 
self microemulsifying mixture with Isradipine was used 
for DSC and X-ray diffraction experiments. To make the 
spectra clearer, only self microemulsifying system 
containing Isradipine adsorbed on to the adsorbent was 
used for the study. 
Differential Scanning Calorimetery (DSC): DSC was 
performed using Perkin Elmer 1020 series DSC-7 
thermal analysis system. Samples (2-3 mg) were heated 
in hermetically sealed aluminium pans under nitrogen 
flow (60 Kg/cm2) at a scanning rate of 10°C/min from 25 
ºC to 300 ºC. Empty aluminium pan was used as a 
reference. The DSC thermograms were obtained for 
Isradipine, placebo mixture, physical mixture and solid 
self microemulsifying mixture with Isradipine. 
X-Ray Powder Diffraction (XRPD): XRPD patterns of 
samples were recorded at room temperature on Bruker’s 
D8 advance diffractometer with Cu Kα radiation (1.54 
Å), at 40 kV, 40 mA passing through nickel filter. 
Analysis was performed in a continuous mode with a 
step size of 0.02° and step time of 1 sec over an angular 
range of 2- 40° 2θ. Obtained diffractograms were 
analyzed with DIFFRAC plus EVA (version 9.0) 
diffraction software. 
In-Vitro Drug Release: To prove that, formulated SME-
OPT has the controlled release characteristic; in-vitro 
drug release of the all trial formulations were carried out 
using USP recommended dissolution condition for 
Isradipine capsules. The conditions are using paddle 
apparatus USP type II dissolution apparatus (Paddle, 50 
S. No. Parameters Conditions 
1 Inlet temperature 40 ºC - 50 ºC 
2 Exhaust temperature 32 ºC - 42 ºC 
3 Pan speed 5 – 10 rpm 
4 Spray speed 1 – 4 g/min 
5 Atomization 0.1 mPa 
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rpm, 37 ºC ± 0.5 ºC). The dissolution medium consisted 
of 500 ml of 0.1% aqueous solution of lauryl dimethyl 
amine oxide. The experiment was carried out under sink 
condition. At predetermined time intervals, 5 ml samples 
were withdrawn and the drug concentration was 
determined by UV spectrophotometer at 328 nm after 
suitable dilution. The volume removed was replaced 
each time with fresh dissolution medium. 
Formulation optimization 
Following formulation variables were optimized for 
desired product characteristics- 
 Selection and quantity of osmotic agents 
 Composition of semi-permeable coating 
 % weight gain for coating layer  
 Quantity of carbonated systems 
Accelerated stability studies: Optimized formulations 
of isradipine SME-OPT 10 mg were packed in HDPE 
Bottle pack and aluminum-aluminium blister packs. The 
packed formulations were stored in stability chambers 
maintained at 40 ºC and 75% RH for 3 months. The 
samples were withdrawn periodically and evaluated for 
dissolution profiling studies and other parameters. 
Similarity factor (f1) and difference factor (f2) were 
evaluated for comparison of dissolution profile of both 
stability batches. 
RESULTS & DISCUSSION 
Analytical method for estimation of Isradipine 
Experimentally λmax in different medium such as 
methanol, 5:95 ratio mixture of methanol and 0.1% 
aqueous solution of lauryl dimethyl amine oxide was 
determined & found to be 328 nm. The coefficient of 
correlation showed excellent correlation between 
concentration and absorbance with the coefficient of 
variance (CV) of 0.999. The relation between drug 
concentration and absorbance is linear and the curves 
obey Beer-Lambert’s law within the concentration range 
of 5-25 µg/ml of isradipine.  
 
Table 3: Concentration and absorbance of standard drug solution 
S. No. 
in 5:95 ratio mixture of methanol and 0.1% 
aqueous solution of lauryl dimethyl amine oxide 
Concentration (µg/ml) Absorbance 
1 5 0.26 
2 10 0.52 
3 15 0.77 
4 20 1.04 
5 25 1.28 
 
Drug-Excipients Compatibility Study 
Following excipients were screened with their respective 
ratios. Physical observation at Initial and after 4 weeks 
exposure was recorded and tabulated. It was clear that, 
Isradipine drug substances was compatible with all the 
excipients used for the study, as there was no change in 
description. Also, there was no significant reduction in 
drug content. 
 
Table 4: API–Excipient compatibility study: Physical Observations and drug content 
S. 
No. 
API: Excipient Mixture Ratio 
Observation Drug Content (Isradipine) 
Initial 
40ºC±2ºC /75%±5% 
RH- 4 Weeks 
Initial 
40ºC±2ºC / 
75%±5% RH- 4 
Weeks 
1 Isradipine (ISDP) - Yellow Powder Yellow Powder 99.65 99.34 
2 ISDP : Magnesium stearate 1 : 2 Yellow Powder Yellow Powder 98.67 98.56 
3 ISDP : HPMC 3 cps 1 : 2 Yellow Powder Yellow Powder 99.56 99.23 
4 ISDP : PEG 400 1 : 2 Yellow Powder Yellow Powder 100.5 99.70 
6 ISDP: Gelucire 50/13 1 : 5 Yellow Powder Yellow Powder 99.32 99.30 
7 ISDP: Transcutol P 1 : 5 Yellow Powder Yellow Powder 98.76 98.76 
8 ISDP: Lutrol F 127 1 : 5 Yellow Powder Yellow Powder 99.54 99.10 
9 ISDP: Polyplasdone XL 1 : 5 Yellow Powder Yellow Powder 99.56 99.45 
10 ISDP: Citric acid 1 : 5 Yellow Powder Yellow Powder 99.09 98.76 
11 ISDP: NaHCO3 1 : 5 Yellow Powder Yellow Powder 98.76 98.50 
12 ISDP: Cellulose acetate 1 : 5 Yellow Powder Yellow Powder 98.51 98.56 
13 ISDP:Crosscarmellose Na 1 : 5 Yellow Powder Yellow Powder 99.98 99.12 
14 ISDP: Neusilin US 2 1 : 20 Yellow Powder Yellow Powder 99.67 99.40 
15 ISDP: Lactose 1 : 20 Yellow Powder Yellow Powder 99.64 99.45 
16 ISDP: Mannitol 1 : 20 Yellow Powder Yellow Powder 99.30 99.20 
17 ISDP: Fructose 1 :20 Yellow Powder Yellow Powder 99.10 98.08 
18 ISDP: Avicel PH 102 1 : 20 Yellow Powder Yellow Powder 99.98 99.50 
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Formulation of liquid self micro-emulsifying drug 
delivery system (SMEDDS) 
Solubility Studies of isradipine in various oils and 
surfactants: To develop a liquid SMEDDS of isradipine, 
suitable oils and surfactants need to be selected. Table 5 
shows measured solubility of drug in various oils and 
surfactant. Among the oils tested, isradipine showed the 
highest solubility in Gelucire 50/13 and was selected as 
an oil phase for the formulation of SMEDDS. From 
solubility studies, it was concluded that isradipine 
showed maximum solubility in Lutrol F127 followed by 
Transcutol P. Lutrol F127 was selected as surfactant and 
Transcutol P as a co-surfactant. 
Solubility Studies of isradipine in various ratio of 
surfactant ratio: Selection of oils, surfactant co-
surfactant and the surfactant/co-surfactant ratio plays an 
important role in the formulation of SMEDDS. Solubility 
of isradipine in various ratio of Transcutol: Lutrol F 127 
(1:1.1, 1:1.3, and 1:1.5) was carried out to find out the 
ratio having maximum solubility for isradipine without 
precipitation on dilution with 100 times with water and 
0.1% aqueous solution of lauryl dimethyl amine oxide. 
Table 6 showed Transcutol: Lutrol F127 at ratio of 1:1.3 
and 1:1.5 showed no significant difference and 
maximum solubility for isradipine without precipitation 
observed & ratio of 1:1.3 selected for optimized 
formulation.
 
Table 5: Solubility of isradipine in various oils, surfactants and co-surfactants 
S. No. Excipients (oils) 
Solubility of isradipine 
(μg/ml) 
Excipients 
(Surfactants/ Co-
surfactants) 
Solubility of 
isradipine (μg/ml) 
1 Peceol 10.50 Soluphor P 40.50 
2 Caproyl 90 35.60 Lutrol F127 80.90 
3 Gelucire 44/14 80.60 Tween 20 15.90 
4 Gelucire 50/13 105.60 Tween 80 20.50 
5 Capmul MCM C 8 30.60 Transcutol P 60.50 
6 Isopropyl myristate 40.50 Span 80 10.50 
7 Safflower oil 20.60 Labrasol 40.80 
8 Oleic Acid 40.50 Cremophor EL 4.50 
 
Table 6: Solubility Study of Isradipine in various ratio of Transcutol: Lutrol F127 
S. No. Ratio of Transcutol : Lutrol F 127 Solubility of isradipine (μg/ml) 
1 1 : 1.1 75.50 
2 1 : 1.3 95.60 
3 1 : 1.5 98.30 
 
Preparation of liquid SMEDDS 
Oils, surfactant, surfactant/co-surfactant ratio was selected on the basis of isradipine solubility, Table 7 provides list of 
ingredients finalized for the optimized liquid SMEDDS formulation with their chemical name & solubility. 
Table 7: Finalized formula of liquid self microemulsifying system (SMES) 
S. No. Name of Ingredient Amount (mg) % w/w 
1 Isradipine 10.00 11.63 
2 
Gelucire 50/13 
(Stearoyl macrogol-32 glycerides) 
30.00 34.88 
3 
Lutrol F 127 
(polyoxyethylene polyoxypropyle-ne (70:30)) 
26.00 30.23 
4 
Transcutol P 
(Diethylene glycol monoethyl ether) 
20.00 23.26 
Total 86.00 100.00 
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Evaluation of Liquid SMEDDS and solid SMEDDS 
Results of evaluation of liquid SMEDDS are as follows 
Table 8: Evaluation of Liquid SMEDDS and solid SMEDDS 
 For liquid SMES For Solid SMEDDS 
Z – Average 
Diameter (nm) 
64.78 ± 5.76 68.95 ± 5.20 
Polydispersity 
Index (PDI) 
0.16 ± 0.0645 0.19 ± 0.0567 
Percent 
transmittance 
99.87 ± 0.034 98.12 ± 0.054 
Dilution Potential 
 
No signs of precipitation or phase 
separation of microemulsion. 
No signs of precipitation or phase 
separation of microemulsion. 
Zeta Potential 
 
-14.87 ± 1.54 
High negative value of zeta potential 
indicated stable SMEDDS formulation. 
-13.45 ± 1.79 
High negative value of zeta potential 
indicated stable SMEDDS formulation. 
 
Preparation of Solid SMEDDS (S-SMEDDS) 
Finally, Neusilin US2, a synthetic, amorphous 
magnesium alumino- metasilicate, was chosen for its 
high liquid adsorptive capacity (due to its very small 
particle size and large specific surface area), and its good 
compressibility compared to the considered silica 
derivatives. An additional reason for preferring 
Neusilin® US2 was its greater surface area (355.5 m2/g 
in respect to 268.4 m2/g of Aeroperl® 300) and its higher 
mesoporosity (1.0 and 0.5 cm3/g, respectively). In fact, it 
is foreseeable that these favourable properties should 
allow a more homogeneous and very fine dispersion of 
the adsorbed drug solution, enabling its rapid re-
dissolution when in contact with the dissolution medium. 
Physical Characterization of isradipine in solid 
SEDDS 
Differential Scanning Calorimetery (DSC): The DSC 
study of Pure Isradipine API, Physical mixture, Liquid 
Isradipine SMES and solid Isradipine self 
microemulsifying system were performed and results 
mentioned in fig. I. Isradipine exhibited a sharp 
endothermic peak at 168°C to 172°C, which 
corresponded to its melting point. The DSC curve of the 
physical mixture also showed the peaks around 170 °C, 
owing to Isradipine crystals present in physical mixture 
but intensity of the isradipine peak was reduced as the 
drug content was low in the physical mixture. The 
disappearance of the endothermic peak of isradipine 
from the thermogram of Liquid isradipine SMES, Solid 
isradipine SMEDDS compared with the thermogram of 
Isradipine API and physical mixture proved that the self 
emulsifying system results into conversion of crystalline 
isradipine to amorphous in solid SEDDS. Conversion of 
crystalline to amorphous is considered as perquisite for 
enhanced dissolution and bioavailability. 
X-Ray Powder Diffraction (XRPD): From X-ray 
powder diffractograms shown in Fig. I, it is clear that, 
the internal physical state of isradipine in the solid 
SMEDDS was further verified. Due to the dilution by 
adsorbent, a few peaks appeared in the physical mixture 
of isradipine and adsorbant (curve b). No obvious peaks 
representing crystals of isradipine were seen for the solid 
SMEDDS (curve c). The XRD patterns of self 
microemulsifying mixture containing Isradipine 
exhibited the absence of characteristic diffraction peaks 
of Isradipine, indicating that the crystalline characteristic 
of Isradipine has disappeared in this self 
microemulsifying mixture. 
 
 
Figure 1: DSC Thermograms of a) Pure Isradipine Powder b) Physical mixture c) Liquid Isradipine SMES d) 
Solid Isradipine SMEDDS and Powder X Ray diffractograms of a) Pure Isradipine Powder b) Physical mixture 
c) Solid isradipine SMEDDS 
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Preparation of EOP incorporating Isradipine S-SMEDDS 
Preliminary Trial 
Table 9: Detailed composition of trial batch T4 and T5 
S. No. Name of ingredients 
Trial No. and Composition (mg/tab) 
T 4 T 5 
Core tablet   
1 Isradipine SMES 86.00 86.00 
2 Neusilin US 2 86.00 86.00 
3 Lactose 99.00 139.00 
4 Mannitol 99.00 139.00 
5 Citric acid -- 10.00 
6 Sodium bicarbonate -- 10.00 
7 Hydroxypropylmethyl cellulose 3 cps 24.00 24.00 
8 Magnesium stearate 6.00 6.00 
Core tablet weight 400.00 500.00 
9 Cellulose acetate 12.00 15.00 
10 PEG 400 8.00 10.00 
11 Acetone q.s. q.s. 
12 Methanol q.s. q.s. 
Coated tablet weight 420.00 525.00 
 
Isradipine SME-OPT is basically an elementary osmotic 
pump tablet. Isradipine is practically insoluble in water. 
In liquid SMEDDS development drug was solubilized 
using self microemulsifying system, which is an essential 
criteria for development of elementary osmotic pump. 
Initial aim of the trial batches was only to achieve release 
of drug from EOP, irrespective of the amount of drug 
release. Table 9 gives detailed composition of trial batch 
T4 and T5. The coating composition & weight gain was 
kept constant at 5% for these trials. 
 
Table 10: Physical and chemical parameters of Trial T 5 
Parameters Values for core tablets of Trial T5 
General appearance Light yellow biconvex tablets 
Tablet weight range (mg) 495.69 – 503.78 
Thickness range (mm) 5.89 – 5.98 
Hardness range (kp) 6.5 – 7.3 
Friability (% w/w) 0.09 
Drug content/Assay (% of label claim) 99.20 
Content uniformity 98.3 -102.1%. 
 
In vitro dissolution study 
The dissolution study is the key in formulation 
development and the dissolution result of a formulation 
was used for further changes in formulation till the 
desired result is achieved. Given below are the 
dissolution profiles of the initial trial batches carried out 
during formulation development process. 
 
 
Figure 2: Comparative dissolution profiling of trials T 4 and T 5 
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In formulation T 4, drug release was found to be 40.50 % 
within 12 hours. This release of drug was incomplete and 
slow.  
So, it was necessary to search out the factors and their 
optimum concentration in order to improve release of 
drug. It was reported that citric acid & sodium 
bicarbonate can be used as a carbonated system to 
enhance the process of emulsification24, so in batch T 5, 
carbonated systems were included, which results in drug 
release up to 76 % as shown in figure II, and the release 
was greater than batch T 4 but still insufficient.  
From batch T 4, & T 5, it was confirmed that prepared 
elementary osmotic pump tablet allows the release of 
drug over 12 hours. 
Next aim was to achieve complete release of drug from 
self microemulsifying osmotic pump tablet (SME-OPT). 
It was hypothesized that, drug release from Batch T 5 
was incomplete which may be due to following reasons. 
 Osmotic agent used was insufficient to force out the 
drug from SME-OPT for the period of 12 hours 
 Amount of carbonated system used to fasten the 
process of emulsification may be insufficient. 
 Optimization of coating composition and % weight 
gain of semipermeable coating and diameter of 
orifice. 
Formulation optimization  
Following formulation variables were optimized for Trial 
T5 for desired product characteristics- 
 Selection and quantity of osmotic agents 
 % weight gain for coating layer 
 Composition of semi-permeable coating 
 Quantity of carbonated systems 
The optimized formulation was evaluated for- 
 Mathematical modeling of drug release 
 Accelerated stability studies 
Selection and quantity of osmotic agents 
Trials were carried out to check effect of different 
osmotic agent individually or in combination on drug 
release. Trials were taken with different types of osmotic 
agents like, fructose, lactose and Mannitol and 
combination of them and finalized based upon the 
dissolution profiling. 
Composition of trials for optimization of osmotic 
agents 
 Trial T5: With 139.00 mg of Lactose and 139.00 mg 
of Mannitol 
 Trial T6: With 189.00 mg of Lactose and 189.00 mg 
of Mannitol 
 Trial T7: With 378.00 mg of Lactose 
 Trial T8: With 378.00 mg of Mannitol 
 Trial T9: With 189.00 mg of Lactose and 189.00 mg 
of Fructose 
 Trial T10: With 189.00 mg of Mannitol and 189.00 
mg of Fructose 
 
 
Figure 3: Comparative dissolution profiling of trials (T5, T6, T7, T8, T9 and T10) 
Inference: It was found that, there was observed 
incomplete isradipine release for the trials with only 
lactose (T7) and only Mannitol (T8). Also observed is 
the complete and controlled release with trials with 
combination of osmotic agents in case of increased 
quantity of lactose and Mannitol (T6), combination of 
increased quantity of lactose and fructose (T9) and 
combination of increased quantity of Mannitol and 
fructose (T 10). 
Conclusion: It was concluded that, any single osmotic 
agent will not be suitable for controlled and complete 
release of isradipine from designed SME-OPT, and 
combination of any of the two osmotic agents from 
Lactose, Mannitol and fructose is required for complete 
and controlled release. 
Optimization of % weight gain for semi-permeable 
coating 
Trials were taken with different % weight gains of semi-
permeable coating keeping all other formulation and 
processing conditions identical. Acceptable range of % 
coating weight gain was established depending upon 
dissolution profiling of trials. 
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Composition of trials for optimization of osmotic 
agents 
 Trial T10: With 5% coating weight gain 
 Trial T11: With 6% coating weight gain  
 Trial T12: With 7% coating weight gain 
 Trial T13: With 8% coating weight gain 
 Trial T14: With 10% coating weight gain 
 
 
Figure 4: Comparative dissolution profiling of trials (T10, T11, T12, T13, and T14) 
Inference: Complete and controlled release was 
obtained with 5% (T10), 6% (T11) and 7% (T12) of 
coating system weight gains. It was found that, there was 
observed incomplete release for the trial with 8% weight 
gain (T13). Trial T 14 was taken with 10 % weight gain 
of coating system and it shows very slow and incomplete 
release of isradipine. 
Conclusion: It was concluded that, as % weight gain and 
quantity of osmotic coating per tablet increases, the 
dissolution profile was slow and incomplete beyond 8% 
weight gain of coating system. Acceptable dissolution 
profiling was confirmed with range of 5 % to 7% of 
coating polymer system. 
Composition of semi-permeable coating 
To study the influence of amount of PEG-400 on the 
drug release profiles, coating % weight gain was kept 
constant at 6% & CA membranes were plasticized with 
20%, 30%, 40%, 50%, and 60% of PEG-400 and 
dissolution studies were carried out. 
Composition of trials for optimization of osmotic agents 
 Trial T10: With 40% PEG in film coating 
composition 
 Trial T15: With 20% PEG in film coating 
composition 
 Trial T16: With 30% PEG in film coating 
composition 
 Trial T17: With 50% PEG in film coating 
composition 
 Trial T18: With 60% PEG in film coating 
composition
 
 
Figure 5: Comparative dissolution profiling of trials (T10, T15, T16, T17 and T18) 
Inference: It is evident that increase in PEG 400 level 
leads to increase in drug release. Complete and 
controlled release was obtained with 40% PEG 400 
(T10), and 30% PEG 400 (T16) used as plasticizer. Trial 
(T15) with 20% PEG 400 used as plasticizer showed 
very slow and incomplete release. Trials with 50% PEG 
400 (T17) and 60% PEG 400 (T18), isradipine drug 
release was somewhat rapid and uncontrolled. 
Conclusion: It was concluded that, as % of plasticizer 
increase in semipermeable coating of SME-OP Tablets, 
there was corresponding increase in rate of drug release. 
Acceptable dissolution profiling was confirmed with 
range of 30 % to 40% of PEG 400 used as plasticizer in 
semi-permeable membrane. 
Optimization of Quantity of carbonated systems 
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To study the influence of amount of citric acid and 
sodium bicarbonate on the drug release profiles, all other 
formulation components were kept constant as per Trial 
T10 and quantity of citric acid-sodium bicarbonate 
varied to assess the impact of it on dissolution profiling. 
Composition of trials for Optimization of Quantity of 
carbonated systems 
 Trial T10: Batch with 10 mg each of Sodium 
bicarbonate and citric acid 
 Trial T19: Batch without carbonated system 
 Trial T20: Batch with 15 mg each of Sodium 
bicarbonate and citric acid 
 Trial T21: Batch with 20 mg each of Sodium 
bicarbonate and citric acid  
 Trial T22: Batch with 40 mg each of Sodium 
bicarbonate and citric acid 
 
Figure 6: Comparative dissolution profiling of Trials (T10, T19, T20, T21 and T22) 
 
Inference: A batch (T19) taken without carbonated 
systems is showing slow and in complete release of 
isradipine from SME-OPT. Trial batch (T20) and (T21) 
with slightly increased quantity of citric acid-sodium bi-
carbonate are showing similar and controlled and 
complete release of Isradipine from SME-OPT. A trial 
(T22) with 40 mg each of citric acid and sodium bi-
carbonate is showing uncontrolled and rapid release of 
Isradipine from SME-OPT and levels above this are not 
studied. 
Conclusion: It was concluded that, as quantity of 
carbonated systems increase in SME-OP Tablets, there 
was corresponding increase in drug release. Acceptable 
dissolution profiling was confirmed with range of 10 mg 
to 20 mg of citric acid and same amount of sodium bi-
carbonate used as carbonated system for controlled 
release of Isradipine from SME-OPT. 
From all above formulation composition optimization 
trials, it was concluded that controlled & maximum drug 
release was achieved in batch T 21, so this batch 
composition was subjected to extensive evaluation and 
process optimization. 
Formula & dissolution profile of optimized trial T 21 
shown in Table 34 & figure VII respectively. 
 
Table 11: Optimized Formula of Isradipine Self-Microemulsifying Osmotic Pump Tablet. (Trial T 21) 
S. No. Name of ingredients 
Composition 
(mg/tab) 
Core tablet  
1 Isradipine SMES 86.00 
2 Neusilin US 2 86.00 
3 Mannitol 179.00 
4 Fructose 179.00 
5 Citric acid 20.00 
6 Sodium bicarbonate 20.00 
7 Hydroxypropylmethyl cellulose 3 cps 24.00 
8 Magnesium stearate 6.00 
Core tablet weight 600.00 
9 Cellulose acetate 18.00 
10 PEG 400 12.00 
11 Acetone q.s. 
12 Methanol q.s. 
Coated tablet weight 630.00 
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Figure 7: Dissolution profiling of finalized Isradipine SME-OPT (Trial T 21) 
 
Evaluation of finalized SME-OPT composition 
Mathematical modeling of drug release 
In order to study the drug release mechanism of the 
finalized SME-OP tablet (T21), the dissolution profiles 
were analyzed according to the zero-order, first-order, 
Higuchi’s square root equations and Korsemeyer Peppas 
equation (Table 12. and Fig VIII). Best goodness-of-fit 
test (R2) was taken as criteria for selecting the most 
appropriate model. The drug release mechanism was best 
explained by Zero order equation, as the plots showed 
the highest linearity (r2 = 0.995). As the drug release was 
best fitted in zero order kinetics, it indicated that the rate 
of drug release is concentration independent. 
 
 
Figure 8: Mathematical modeling of drug release profile (a) Zero order plot, (b) First order plot, (c) Higuchi plot, (d) 
Korsemeyer Peppas Kinetics 
Accelerated stability studies 
The evaluations of Isradipine SME-OP Tablets exposed to accelerated stability conditions of 40ºC and 75% RH were 
carried out in HDPE Bottle pack and the results were given below. 
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Table 12: Evaluation of tablet exposed to accelerated stability condition 
Storage Condition 40 ºC and 75% RH (Pack-HDPE bottle) 
Tablet evaluation 
Parameters 
Sampling Schedule 
Initial 12 Weeks 24 Weeks 
Description 
Coated, 
biconvex tablet 
Coated,  biconvex 
tablet 
Coated, 
biconvex tablet 
Diameter (mm) 11.04 – 11.08 11.05 – 11.09 11.04 – 11.07 
Thickness (mm) 6.20 – 6.26 6.24 – 6.27 6.22 – 6.28 
Drug Content (%) 99.18 98.79 99.25 
Water Content  
(% LOD) 
2.54 2.89 2.92 
Dissolution profiling    
f 1 Value with Initial 
Sample 
NA 5.4 4.8 
f 2 Value with Initial 
Sample 
NA 69.9 73.8 
  
Inference: The stability testing results showed that there 
was no change in physical parameters like description, 
dimensions of the tablet, after 24 weeks when stored in 
HDPE Bottle pack at 40 ºC and 75% RH. There was no 
significant change in drug content of isradipine when 
stored in HDPE Bottle over 24 weeks. As there was no 
change in drug content, it can also be concluded that, 
there was no significant generation of Isradipine 
impurities. f1 and f2 values calculations also showed 
that, there was no change in dissolution profiling after 
stability studies compared to initial control sample. 
CONCLUSION 
The current study illustrates the formulation of self 
micro-emulsifying osmotic pump tablet system of model 
drug isradipine, where in Isradipine is water insoluble 
anti- hypertensive drug administered as extended release 
formulation for prolonged duration. Solubility of 
Isradipine was significantly increased by use of self 
micro-emulsifying system. It can be explained by 
conversion of crystalline nature to more soluble 
amorphous nature when formulated as solid self 
microemulsifying system, as endorsed by PXRD and 
DSC studies. Various oils, surfactants, co-surfactants and 
adsorbents were screened for suitability for incorporation 
in SME-OPT. The formulation involved a stable self 
micro-emulsifying liquid concentrate incorporating 
isradipine formulated as directly compressible tablet 
using selected Neusilin US2 as adsorbent for SMES. 
Final manufacturing process involves coating of Self 
micro-emulsifying core tablets with semi-permeable 
coating polymer system and drilling of orifice to create 
self micro-emulsifying osmotic pump tablet (SME-OPT). 
Final composition was optimized for quantity of osmotic 
agents, carbonated systems, % weight gain for coating 
membrane, composition of coating system. Mathematical 
modeling data showed that drug release from self 
emulsifying pump tablet follows zero order release 
kinetic, for period of 12 hour - a highly desirable 
characteristics of controlled release formulation. Final 
coated tablet formulation was found to be stable when 
stored in HDPE bottle pack at 40°C/75% RH for 24 
weeks. The developed novel SME-OPT of Isradipine 
will be a promising template for formulating controlled 
release dosage form of BCS Class II and IV bioactive 
agents. The technology used for the preparation of SME-
OPT is relatively simple manufacturing technology 
which can be easily adopted in industrial units on a 
commercial scale. 
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